ImidaclopridImidacloprid was the first commercialized member of a new class of insecticides called chloronicotinyl nitroguanidines or neonicotinoids. First synthesized in its active form by Bayer HealthCare in Japan in 1986, it was developed for control of a variety of insects for both agricultural and veterinary purposes. A novel 10% spot-on formulation of imidacloprid, Advantage, has been available for the control of fleas on dogs and cats since 1996. Due to its rapid and highly effective activity against fleas and favorable safety profile, imidacloprid has proven to be a remarkable advancement in flea control for pets. Table 1: Physicochemical Properties of Imidacloprid
Mode of ActionImidacloprid acts as an agonist on the postsynaptic nicotinic acetylcholine receptors of motor neurones in insects (Fig.2). This causes an over-stimulation of the nervous system, and ultimately kills the insect1. Following topical application, imidacloprid localises in the water-resistant lipid layer of the skin surface. Fleas do not need to bite an animal in order to be exposed to imidacloprid; rather, it is absorbed through the flea’s non-sclerotised intersegmental membranes2. Distribution of imidacloprid after topical applicationImidacloprid is spread over the skin surface and throughout the hair coat of dogs and fur of cats within twelve hours after topical application. Due to the greater surface area of larger dogs, application at multiple spots maximizes the translocation and coverage of imidacloprid
Spectrum of Activity
Based on its favorable profile in mammals, imidacloprid was developed for veterinary use and is widely used for flea control in companion animals. The target ectoparasites include various species of fleas (Ctenocephalides spp.), as well as biting (Trichodectes canis) and sucking (Linognathus setosus) lice3. Imidacloprid is registered for use in dogs and cats throughout the world, as well as for rabbits in some countries. In addition to rapid and potent adulticidal activity against fleas present on dogs and cats, imidacloprid has been shown to have significant flea larvicidal activity, both in laboratory studies as well as in simulated home environments4, 5. This is important as immature stages present in the pets’ surroundings are a reservoir of reinfestation. Flea larvae in the pet’s surroundings are killed after contact with a pet treated with imidacloprid. Exposure of larvae to these minute quantities of imidacloprid in the environment of treated pets results in marked reduction of developing flea populations in comparison to environments of untreated animals. In this way, it is probable that the larvicidal effects of imidacloprid are of practical significance in breaking the flea life cycle and in reducing the level of flea infestation in the domestic environment6. Advocate for cats Advocate for dogs
1 also known as French Heartworm ToxicologyImidacloprid has highly selective binding affinity for insect nicotinic acetylcholine receptors, as well as the fact that insects have much higher numbers of these receptors than vertebrate species. Therefore, the compound is very well tolerated by mammals. Results of acute toxicological studies in laboratory animals (Table 2) support the low mammalian toxicity, especially when one considers the dermal route of application used in companion animals. Additionally, imidacloprid has been demonstrated to be non-carcinogenic, non-mutagenic and non-teratogenic in numerous laboratory evaluations. Table 2: Toxicological data for Imidacloprid
LD50 = dosage resulting in 50% mortality in treatment group. LC50 = concentration producing 50% mortality in the treatment group. Questions about the product?If you have any questions about the product, please contact our Veterinary Service. References
|
Contact for specific questions Veterinary Services
|
||||||||||||||||||||||||||||||||||||
Last changed: 19.11.2008 | |||||||||||||||||||||||||||||||||||||